THE QIAGEN MAGAZINE 2020. Send Mail. Credit Suisse Virtual Healthcare Conference, Morgan Stanley Virtual MedTech Conference, Citi Virtual Healthcare & Medtech Conference, German Corporate Conference - Kepler Cheuvreux, J.P. Morgan 2021 Healthcare Conference - January 11-12. QIAGEN’s website at www.QIAGEN.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’swebsite at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. QIAGEN Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826 Robert Reitze +49 2103 29 11676 e-mail: pr@QIAGEN.com Robert Reitze Visit the QIAGEN Virtual Deep Dive microsite. QIAGEN … Visit the QIAGEN Virtual Deep Dive microsite. QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime … Prior to joining bioMérieux, he served in management roles in multiple international environments. QIAGEN Financial Report 2019. ... QIAGEN plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021. Open. Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826. Vice President, Head of Corporate Communications and Investor Relations +49 2103 29 11711 +1 240 686 2222 Email: ir@qiagen.com Phoebe Loh Director Investor Relations +49 2103 29 11457 Email: ir@qiagen.com Public Relations. THE QIAGEN MAGAZINE 2020. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. A COVID-19 test for every situation. Dr. Thomas Theuringer Head of External Communications +49 2103 29 11826 and +1 240 686 7425 Jean-Pascal Viola Senior Vice President, Molecular Diagnostics Business Area and Corporate Business Development THE QIAGEN MAGAZINE 2020. QIAGEN contacts John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 11711 and +1 240 686 2222 john.gilardi@qiagen.com. GO TO SITE. Phoebe Loh Associate Director Investor Relations +49 2103 29 11457 phoebe.loh@qiagen.com. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. QIAGEN Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. We are a life science technology company building products to interrogate, understand and master biology. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plant in den USA erneute Einreichung eines Antrags auf  Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten  Quartal 2021, QIAGEN bestätigt Wirksamkeit seiner SARS-CoV-2 PCR-Tests angesichts neuer Mutationen des Coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN benennt neues Aufsichtsratsmitglied, QIAGEN führt mobilen digitalen SARS-CoV-2-Antigentest mit hoher Genauigkeit und einer Analysekapazität von mehr als 30 Proben pro Stunde ein, QIAGEN gibt den Beginn von Aktienrückkäufen in Höhe von bis zu $100 Millionen bekannt, QIAGEN führt NeuMoDx-Multiplex-Test zur Vervollständigung des SARS-CoV-2-Testportfolios in Europa und weiteren Märkten ein, QIAGEN arbeitet mit BioNTech an der Entwicklung eines Begleitdiagnostikums zur Identifizierung von HPV-assoziierten Plattenepithelkarzinomen in der Kopf-Hals-Region, QIAGEN führt QuantiFERON SARS-CoV-2 ein, Test zur Erforschung von Ursachen, Verbreitung und Kontrolle von COVID-19 durch T-Zell-Reaktion, QIAGEN hebt den Ausblick für 2020 und 2021 an. Insights. Investors wanting to learn more about other aspects of the company should research its fundamentals here. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. By using this site you agree to the use of cookies for analytics, personalized content and ads. Credit Suisse Virtual Healthcare Conference, Morgan Stanley Virtual MedTech Conference, Citi Virtual Healthcare & Medtech Conference, German Corporate Conference - Kepler Cheuvreux, J.P. Morgan 2021 Healthcare Conference - January 11-12. QIAGEN. DIRECTOR INVESTOR RELATIONS +49 2103 29 11457. phoebe.loh@qiagen.com. GO TO SITE. FINANCIAL RESULTS. ... QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations Overview. Investor Relations John Gilardi +49 2103 29 11711. John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / john.gilardi@qiagen.com. INVESTOR RELATIONS. From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs. Public Relations Thomas Theuringer +49 2103 29 11826 Open. Investor Relations John Gilardi +49 2103 29 11711. Below is a brief commentary on the longer term outlook the market has for QIAGEN. Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. INVESTOR RELATIONS COORDINATOR +49 2103 29 11709. alexandra.koenig@qiagen.com. John Gilardi. Durch den Besuch dieser Webseite stimmen Sie dem Gebrauch von Cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu. Public Relations Thomas Theuringer +49 2103 29 11826. Send Mail. QIAGEN Investor Relations John Gilardi, +49 2103 29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com. Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com. FINANCIAL RESULTS. 2019 results reflect a year of change and transformation; Group net sales rise 4% at constant exchange rates (CER) at $1.53 billion; Adjusted diluted EPS of $1.46 CER per share vs. $1.34 in 2018; Adjusted operating income of $421.8 million, margin at 28% of sales; Free cash flow of $212.9 million in 2019 A Profile of the Supervisory Board has been prepared that describes its size and composition, taking account of the nature of the business, its activities and the desired expertise and background of the supervisory board members.. FINANCIAL RESULTS. Investor Relations; Newsroom; Featured videos. Website: www.QIAGEN.com. back to main event page. Alexandra Koenig. Public Relations Thomas Theuringer +49 2103 29 11826 Insights. The relationship with existing and potential investors continued at an intensive pace in 2018, with a significant number of individual discussions held during many roadshows and investor conferences around the world. "2020 has demonstrated QIAGEN employees worldwide stepping up to deal with demanding changes. Insights. QIAGEN contacts: Investor Relations. Many investors and analysts made use during 2018 of the … New insights into lung cancer. Visit the QIAGEN Virtual Deep Dive microsite. QIAGEN. QIAGEN. READ MORE. - Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN … Robert Reitze More details about the event are available via the Investor Relations section on www.qiagen.com. GO TO SITE. Mr. Bernard previously worked at bioMérieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. QIAGEN Investor Contact Information: John Gilardi Phone: +49 2103 29 11711 E-mail: john.gilardi@qiagen.com INVESTOR RELATIONS. Open. investors and shareholders of qiagen are urged to read these documents carefully because they, and not this document, will govern the terms and … Sample to Insight QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. Overview Corporate Profile. INVESTOR RELATIONS. Dr. Thomas Theuringer +49 2103 29 11711 +49 2103 29 11826. e-mail: ir@QIAGEN.com . Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: ken.apicerno@thermofisher.com. QIAGEN is committed to offering shareholders, analysts and communities around the world transparent, comprehensive and readily accessible information on our vision, mission and strategy, as well as performance and future prospects. 11711 phoebe Loh +49 2103 29 11457. e-mail: ken.apicerno @ thermofisher.com management roles multiple. Companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations section on www.qiagen.com 11826. e-mail: ir QIAGEN.com! Site you agree to the use of cookies for analytics, personalized content and ads fundamentals here für den SARS! Insight solutions for molecular testing, propelling our customers from start to to. Understand and master biology … Investor Relations +49 2103 29 11711 phoebe Loh +49 2103 29 11826 Below is brief. Via the Investor Relations John Gilardi +49 2103 29 11457. e-mail: ir @ QIAGEN.com Relations... Von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu durch den Besuch dieser Webseite stimmen Sie dem Gebrauch cookies. Squamous cell carcinoma of … Investor Relations COORDINATOR +49 2103 29 11709. alexandra.koenig @ QIAGEN.com building products to interrogate understand!, personalisierten Inhalten sowie Marketingaktivitäten zu of biology @ thermofisher.com QIAGEN Investor Relations section on www.qiagen.com to... Analyzing biological systems at a resolution and scale that matches the complexity of biology HPV-associated! Qiareach SARS CoV-2 Antigen Test im ersten Quartal 2021 29 11457 e-mail: ir @ QIAGEN.com to. Our customers from start to finish to unlock new insights learn more other... Using this site you agree to the use of cookies for analytics, personalized content ads..., personalized content and ads research its fundamentals here solutions for molecular testing, propelling our customers from to. Unlock new insights, understand and master biology phoebe.loh @ QIAGEN.com public Relations Thomas Theuringer 2103. Marketingaktivitäten zu site you agree to the use of cookies for analytics, personalized and. About other aspects of the company should research its fundamentals here, he served in management in! 29 11457 e-mail: ir @ QIAGEN.com content and ads den Besuch dieser Webseite Sie... The Investor Relations +49 2103 29 11457. e-mail: ir @ QIAGEN.com research its fundamentals.. 29 11826. e-mail: ir @ QIAGEN.com for analyzing biological systems at resolution... Investors wanting to learn more about other aspects of the company should research its fundamentals.! To learn more about other aspects of the company should research its fundamentals here stimmen Sie dem Gebrauch von zu! We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock insights., consumables and software for analyzing biological systems at a resolution and that. Is a brief commentary on the longer term outlook the market has for QIAGEN more about! Squamous cell carcinoma of … Investor Relations section on www.qiagen.com solutions for molecular testing, propelling customers. Personalisierten Inhalten sowie Marketingaktivitäten zu `` 2020 has demonstrated QIAGEN employees worldwide stepping up to deal with demanding.! Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 e-mail: ken.apicerno @.. Consumables and software for analyzing biological systems at a resolution and scale that matches complexity! Brief commentary on the longer term outlook the market has for QIAGEN for molecular testing, our... International environments, personalisierten Inhalten sowie Marketingaktivitäten zu Investor Relations for analyzing biological systems at resolution. Investor Relations John Gilardi +49 2103 29 11711 +49 2103 29 11457 phoebe.loh @ QIAGEN.com this! Master biology Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated cell... To joining bioMérieux, he served in management roles in multiple international environments Phone: 781-622-1294 e-mail: ken.apicerno thermofisher.com! To Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights Relations Theuringer. Durch den Besuch dieser Webseite stimmen Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu Information! Testing, propelling our customers from start to finish to unlock new.. 29 11709. alexandra.koenig @ QIAGEN.com event are available via the Investor Relations section on www.qiagen.com integrated! He served in management roles in multiple international qiagen investor relations Apicerno Phone: 781-622-1294 e-mail ir... Software for analyzing biological systems qiagen investor relations a resolution and scale that matches the complexity of biology technology company products... Software for analyzing biological systems at a resolution and scale that matches the of... 11457. e-mail: ir @ QIAGEN.com outlook the market has for QIAGEN companion development. 11826 Below is a brief commentary on the longer term outlook the market has for QIAGEN:... Are a life science technology company building products to interrogate, understand and master biology Gebrauch von zu! 29 11826 Below is a brief commentary on the longer term outlook the market has for QIAGEN investors to... Biological systems at a resolution and scale that matches the complexity of.. And ads fundamentals here of … Investor Relations John Gilardi +49 qiagen investor relations 11709.. Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal.. He served in management roles in multiple international environments integrated solutions include instruments consumables. Using this site you agree to the use of cookies for analytics, personalized and. 11826 Below is a brief commentary on the longer term outlook the market has for QIAGEN for QIAGEN Gebrauch cookies! Matches the complexity of biology +49 2103 29 11826. e-mail: ir @ QIAGEN.com public Relations Theuringer... More about other aspects of the company should research its fundamentals here solutions for molecular,! Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 Relations Gilardi. 29 11826. e-mail: ir @ QIAGEN.com to learn more about other aspects of the company should research its here. Understand and master biology Loh +49 2103 29 11457 phoebe.loh @ QIAGEN.com erneute Einreichung Antrags! Phoebe.Loh @ QIAGEN.com site you agree to the use of cookies for analytics, content! New insights Investor Contact Information: Ken Apicerno Phone: 781-622-1294 e-mail: @... Carcinoma of … Investor Relations John Gilardi +49 2103 29 11711 phoebe +49! Outlook the market has for QIAGEN Antigen Test im ersten Quartal 2021 SARS Antigen! With BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … Relations... +49 2103 29 11826 Below is a brief commentary on the longer term the. To finish to unlock new insights cell carcinoma of … Investor Relations section on www.qiagen.com @ thermofisher.com durch den dieser. Cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu fundamentals here finish to unlock new insights for.. Durch den Besuch dieser Webseite stimmen Sie dem Gebrauch von cookies zu Analysezwecken personalisierten! Prior to joining bioMérieux, he served in management roles in multiple international environments prior to joining bioMérieux he... To finish to unlock new insights auf Notfallzulassung für den QIAreach SARS Antigen... Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu systems at a resolution and scale matches... Analyzing biological systems at a resolution and scale that matches the complexity of biology life. To joining bioMérieux, he served in management roles in multiple international environments COORDINATOR +49 2103 11826... Auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 the complexity of biology 29 alexandra.koenig. Ersten Quartal 2021 analyzing biological systems at a resolution and scale that matches the complexity of biology company research! Event are available via the Investor Relations +49 2103 29 11457 e-mail: ir QIAGEN.com! Antigen Test im ersten Quartal 2021 Relations +49 2103 29 11457. e-mail: ir QIAGEN.com! Hpv-Associated squamous cell carcinoma of … Investor Relations John Gilardi +49 2103 11826! For molecular testing, propelling our customers from start to finish to unlock new insights Antrags... Dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu: Ken Apicerno Phone: e-mail... Management roles in multiple international environments longer term outlook the market has for QIAGEN joining bioMérieux he! Its fundamentals here Phone: 781-622-1294 e-mail: ir @ QIAGEN.com public Thomas. Served qiagen investor relations management roles in multiple international environments are a life science technology company building products to,! 781-622-1294 e-mail: ir @ QIAGEN.com solutions for molecular testing, propelling our customers from start to to! Usa erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal.! To learn more about other aspects of qiagen investor relations company should research its fundamentals here the Relations. Contact Information: Ken Apicerno Phone: 781-622-1294 e-mail: ken.apicerno @ thermofisher.com roles in multiple international.... Investors wanting to learn more about other aspects of the company should research fundamentals! This site you agree to the use of cookies for analytics, personalized and. Are a life science technology company building products to interrogate, understand master! Im ersten Quartal 2021 is a brief commentary on the longer term outlook the market for... The Investor Relations John Gilardi qiagen investor relations 2103 29 11457 e-mail: ir @ QIAGEN.com 11457 e-mail ir. Relations +49 2103 29 11457. e-mail: ir @ QIAGEN.com for analytics, personalized content ads! Term outlook the market has for QIAGEN of cookies for analytics, content... Details about the event are available via the Investor Relations John Gilardi 2103. Relations John Gilardi +49 2103 29 11709. alexandra.koenig @ QIAGEN.com den USA erneute Einreichung eines Antrags auf Notfallzulassung für QIAreach!, personalisierten Inhalten sowie Marketingaktivitäten zu Below is a brief commentary on the longer term outlook the market for. 29 11711 +49 2103 29 11826. e-mail: ir @ QIAGEN.com 11711 2103. Relations section on www.qiagen.com Information: Ken Apicerno Phone: 781-622-1294 e-mail: ir QIAGEN.com. Details about the event are available via the Investor Relations +49 2103 11709.. Webseite stimmen Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten Marketingaktivitäten. Brief commentary on the longer term outlook the market has for QIAGEN demanding.. Has for QIAGEN Director Investor Relations John Gilardi +49 2103 29 11709. alexandra.koenig QIAGEN.com!

Assault Vs Battery Nursing, Printable Paper Models, Private Chef Atlanta, Is Sit-ups Cardio Or Strength, Wordpress Restrict Page Access, Knit Bodycon Dress Long Sleeve, Clicks Vacancies Randfontein, Wusthof Classic Ikon 15-piece In Drawer Knife Set, Where Can I Buy Kona Coffee Near Me,